tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Discitis D015299 2 associated lipids
Fox-Fordyce Disease D005588 2 associated lipids
Collagen Diseases D003095 2 associated lipids
Multiple Pulmonary Nodules D055613 2 associated lipids
Vestibular Diseases D015837 2 associated lipids
Lichen Planus, Oral D017676 2 associated lipids
Lymphomatoid Granulomatosis D008230 2 associated lipids
Paresis D010291 2 associated lipids
Myxedema D009230 2 associated lipids
Coccidioidomycosis D003047 2 associated lipids
Ileal Neoplasms D007078 2 associated lipids
Encephalitis, Viral D018792 3 associated lipids
Intestinal Atresia D007409 3 associated lipids
Foot Dermatoses D005533 3 associated lipids
Hyperkalemia D006947 3 associated lipids
Epstein-Barr Virus Infections D020031 3 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Hematologic Diseases D006402 3 associated lipids
Immune System Diseases D007154 3 associated lipids
Cardiovirus Infections D018188 3 associated lipids
Castleman Disease D005871 3 associated lipids
Acneiform Eruptions D017486 3 associated lipids
Anus Diseases D001004 3 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Kidney Tubular Necrosis, Acute D007683 3 associated lipids
Scleritis D015423 3 associated lipids
Wounds, Stab D014951 3 associated lipids
Digestive System Diseases D004066 3 associated lipids
Pemphigus, Benign Familial D016506 3 associated lipids
Ileus D045823 3 associated lipids
Anemia, Refractory D000753 3 associated lipids
Pityriasis D010915 3 associated lipids
Uveitis, Intermediate D015867 3 associated lipids
Legionellosis D007876 3 associated lipids
Keratosis, Actinic D055623 3 associated lipids
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Glomerulonephritis, Membranoproliferative D015432 3 associated lipids
Failed Back Surgery Syndrome D055111 3 associated lipids
Perceptual Disorders D010468 3 associated lipids
Toxocariasis D014120 3 associated lipids
Pyoderma Gangrenosum D017511 3 associated lipids
Meningococcal Infections D008589 3 associated lipids
Fetal Hypoxia D005311 3 associated lipids
Lichen Planus D008010 3 associated lipids
Trichomonas Infections D014245 3 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Impetigo D007169 3 associated lipids
Polyneuropathies D011115 3 associated lipids
Nervous System Autoimmune Disease, Experimental D020721 3 associated lipids
Epidermolysis Bullosa D004820 3 associated lipids
Paronychia D010304 3 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Gingival Hyperplasia D005885 3 associated lipids
Facial Neoplasms D005153 3 associated lipids
Gingivitis D005891 3 associated lipids
Hemophilia B D002836 3 associated lipids
Pouchitis D019449 3 associated lipids
Cryptococcosis D003453 3 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Pemphigus D010392 3 associated lipids
Dysgammaglobulinemia D004406 3 associated lipids
Pterygium D011625 3 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Arthritis, Reactive D016918 3 associated lipids
Foot Ulcer D016523 4 associated lipids
Neoplasms, Second Primary D016609 4 associated lipids
Eczema D004485 4 associated lipids
Intracranial Hypertension D019586 4 associated lipids
Red-Cell Aplasia, Pure D012010 4 associated lipids
Neuritis D009443 4 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Dermatitis, Perioral D019557 4 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Epilepsy, Temporal Lobe D004833 4 associated lipids
Cicatrix, Hypertrophic D017439 4 associated lipids
Reflex Sympathetic Dystrophy D012019 4 associated lipids
Optic Nerve Injuries D020221 4 associated lipids
Headache D006261 4 associated lipids
Pain, Intractable D010148 4 associated lipids
Diabetes Complications D048909 4 associated lipids
Balanitis D001446 4 associated lipids
Endomyocardial Fibrosis D004719 4 associated lipids
Amenorrhea D000568 4 associated lipids
Blepharitis D001762 4 associated lipids
Hyperuricemia D033461 4 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Glomerulosclerosis, Focal Segmental D005923 4 associated lipids
Osteoporosis, Postmenopausal D015663 4 associated lipids
Hallucinations D006212 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Meningoencephalitis D008590 4 associated lipids
Herpesviridae Infections D006566 4 associated lipids
Prurigo D011536 4 associated lipids
Viremia D014766 4 associated lipids
Gastroenteritis D005759 4 associated lipids
Hepatitis, Viral, Animal D006524 4 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Gout D006073 4 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Ogunseinde BA et al. A case of tacrolimus (FK506)-induced pancreatitis and fatality 2 years postcadaveric renal transplant. 2003 Transplantation pmid:12883222
Keenan RJ et al. Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506. 1991 Transplantation pmid:1719668
Vathsala A et al. Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation. 1990 Transplantation pmid:1689520
Adams PS et al. Postoperative cardiac tamponade after kidney transplantation: a possible consequence of alemtuzumab-induced cytokine release syndrome. 2013 Transplantation pmid:23380870
Fridell JA et al. Steroid withdrawal for pancreas after kidney transplantation in recipients on maintenance prednisone immunosuppression. 2006 Transplantation pmid:16906038
Hostettler KE et al. Cyclosporine A mediates fibroproliferation through epithelial cells. 2004 Transplantation pmid:15223908
Yang CW et al. Preconditioning with cyclosporine A or FK506 differentially regulates mitogen-activated protein kinase expression in rat kidneys with ischemia/reperfusion injury. 2003 Transplantation pmid:12544865
Lykavieris P et al. Angioedema in pediatric liver transplant recipients under tacrolimus immunosuppression. 2003 Transplantation pmid:12544888
Kiuchi T et al. A hepatic graft tuberculosis transmitted from a living-related donor. 1997 Transplantation pmid:9089234
Donnadieu B et al. Central retinal vein occlusion-associated tacrolimus after liver transplantation. 2014 Transplantation pmid:25955343
Loucaidou M et al. Five-year results of kidney transplantation under tacrolimus-based regimes: the persisting significance of vascular rejection. 2003 Transplantation pmid:14557763
King-Biggs MB et al. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. 2003 Transplantation pmid:12792493
Welberry Smith MP et al. Alemtuzumab induction in renal transplantation permits safe steroid avoidance with tacrolimus monotherapy: a randomized controlled trial. 2013 Transplantation pmid:24056618
Barth RN et al. Prolonged survival of composite facial allografts in non-human primates associated with posttransplant lymphoproliferative disorder. 2009 Transplantation pmid:19996923
Ciancio G et al. Randomized trial of dual antibody induction therapy with steroid avoidance in renal transplantation. 2011 Transplantation pmid:22027927
Thervet E et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. 2003 Transplantation pmid:14578760
Tabasco-Minguillan J et al. Insulin requirements after liver transplantation and FK-506 immunosuppression. 1993 Transplantation pmid:7692637
Jain A et al. Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation. 2000 Transplantation pmid:10972220
Wang SC et al. A dual mechanism of immunosuppression by FK-506. Differential suppression of IL-4 and IL-10 levels in T helper 2 cells. 1993 Transplantation pmid:7692640
Zhao WY et al. Single kidneys transplanted from small pediatric donors less than 15 kilograms into pediatric recipients. 2014 Transplantation pmid:25955345
Prud'homme GJ et al. GABA protects human islet cells against the deleterious effects of immunosuppressive drugs and exerts immunoinhibitory effects alone. 2013 Transplantation pmid:23851932
Coto E and Tavira B Pharmacogenetics of calcineurin inhibitors in renal transplantation. 2009 Transplantation pmid:19667964
Nobori S et al. Long-term acceptance of fully allogeneic cardiac grafts by cotransplantation of vascularized thymus in miniature swine. 2006 Transplantation pmid:16421473
Yu S et al. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. 2006 Transplantation pmid:16421475
Gruber SA et al. Initial results of solitary pancreas transplants performed without regard to donor/recipient HLA mismatching. 2000 Transplantation pmid:10933170
Shapiro R et al. Alopecia as a consequence of tacrolimus therapy. 1998 Transplantation pmid:9603186
Fernandez LA et al. The effects of maintenance doses of FK506 versus cyclosporin A on glucose and lipid metabolism after orthotopic liver transplantation. 1999 Transplantation pmid:10589951
Batten P et al. Human T cell responses to human and porcine endothelial cells are highly sensitive to cyclosporin A and FK506 in vitro. 1999 Transplantation pmid:10589954
Mestres J et al. Late subcapsular lymphocele in a kidney graft. 2012 Transplantation pmid:22487814
Porrini E et al. Prediabetes in patients receiving tacrolimus in the first year after kidney transplantation: a prospective and multicenter study. 2008 Transplantation pmid:18431233
Singla AK et al. Cerulomycin Caerulomycin [corrected] A: a potent novel immunosuppressive agent. 2014 Transplantation pmid:24949498
Walsh C et al. Anti-CD25 monoclonal antibody replacement therapy for chronic kidney disease in liver transplant recipients. 2013 Transplantation pmid:23296149
Kessler L et al. Tacrolimus-associated optic neuropathy after pancreatic islet transplantation using a sirolimus/tacrolimus immunosuppressive regimen. 2006 Transplantation pmid:16495816
Podesser BK et al. Comparison of low and high initial tacrolimus dosing in primary heart transplant recipients: a prospective European multicenter study. 2005 Transplantation pmid:15714171
Shaefer MS et al. Falsely elevated FK-506 levels caused by sampling through central venous catheters. 1993 Transplantation pmid:7689264
Borni-Duval C et al. Risk factors for BK virus infection in the era of therapeutic drug monitoring. 2013 Transplantation pmid:23778568
Mourer JS et al. Late calcineurin inhibitor withdrawal prevents progressive left ventricular diastolic dysfunction in renal transplant recipients. 2012 Transplantation pmid:22955227
Danziger-Isakov LA et al. The risk, prevention, and outcome of cytomegalovirus after pediatric lung transplantation. 2009 Transplantation pmid:19461492
Ferdman RM et al. Rapid intravenous desensitization to antithymocyte globulin in a patient with aplastic anemia. 2004 Transplantation pmid:14743005
Gibson SW et al. Nutritional immunomodulation leads to enhanced allograft survival in combination with cyclosporine A and rapamycin, but not FK506. 2000 Transplantation pmid:10852592
Pirenne J et al. Combined transplantation of small and large bowel. FK506 versus cyclosporine A in a porcine model. 1996 Transplantation pmid:8685944
Burke GW et al. Use of FK 506 in simultaneous pancreas/kidney transplantation: lack of impairment of glycemic or lipid metabolism. 1995 Transplant. Proc. pmid:8539872
Watanabe K et al. Fate of long-surviving allografts in tolerant recipients induced by fractionated lymphoid irradiation, donor bone marrow cell infusion, and FK 506 after retransplantation in dogs. 1993 Transplant. Proc. pmid:7679813
Ryu S and Yasunami Y Prevention of immune rejection in rat islet allografts by continuous SC administration of FK 506 using a mini-osmotic pump. 1991 Transplant. Proc. pmid:1703710
Thomson AW Interspecies comparison of the immunosuppressive efficacy and safety of FK 506. 1990 Transplant. Proc. pmid:1689883
Urbizu JM et al. Immunosuppression using tacrolimus/mycophenolate versus neoral/mycophenolate following kidney transplantation: a single-center experience. 2002 Transplant. Proc. pmid:11959197
Havrdova T et al. Effect of tacrolimus versus cyclosporine on glucose metabolism of pancreas and kidney recipients in the late (> 8 years) posttransplant period. 2011 Transplant. Proc. pmid:22099774
Guitard J et al. Hepatitis C virus viral load after conversion from tacrolimus to cyclosporine in liver transplant patients: a pilot study. 2007 Transplant. Proc. pmid:17954189
Shapiro R et al. Outcome after steroid withdrawal in renal transplant patients receiving tacrolimus-based immunosuppression. 1998 Transplant. Proc. pmid:9636557
Gavela Martínez E et al. Use of basiliximab induction in low-immunological risk renal transplant recipients receiving tacrolimus-based immunosuppression. 2009 Jul-Aug Transplant. Proc. pmid:19715913
Ochiai M et al. Islet toxicity of FK506 measured in canine autografts. 1998 Transplant. Proc. pmid:9532224
Rodrigo E et al. High initial blood levels of tacrolimus in overweight renal transplant recipients. 2005 Transplant. Proc. pmid:15866635
Fung J et al. Randomized trial in primary liver transplantation under immunosuppression with FK 506 or cyclosporine. 1993 Transplant. Proc. pmid:7680146
Martínez-Castelao A et al. Arterial elasticity measurement in renal transplant patients under anticalcineurin immunosuppression. 2005 Transplant. Proc. pmid:16386539
Christians U et al. Interactions of FK 506 and cyclosporine metabolism. 1991 Transplant. Proc. pmid:1721280
Andereggen E et al. Immunohistological study of islet xenograft rejection in immunosuppressed recipients. 1996 Transplant. Proc. pmid:8623420
Serrano M et al. Clinical value of a single determination of intracellular ATP levels in stimulated CD4+ T lymphocytes in pediatric patients with stable liver transplantation. 2012 Transplant. Proc. pmid:23146475
Bilodeau JF et al. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium. 2009 Transplant. Proc. pmid:19917367
McAlister VC et al. Cost of liver transplantation using tacrolimus. 1998 Transplant. Proc. pmid:9636611
Ohtsuka S et al. Effect of splenectomy on hamster-to-rat pancreas xenotransplantation. 1994 Transplant. Proc. pmid:7518109
Oppenheimer F Steroid withdrawal in renal transplant recipients. 2000 Transplant. Proc. pmid:10686314
Porayko MK et al. Comparing nephrotoxicity of FK 506 and cyclosporine regimens after liver transplantation: preliminary results from US Multicenter trial. U.S. Multicenter Liver Study Group. 1995 Transplant. Proc. pmid:7533358
Tamura A et al. Combination effect of tacrolimus and FTY720 in liver transplantation in rats. 1999 Transplant. Proc. pmid:10578290
Wang SC et al. FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line. 1991 Transplant. Proc. pmid:1721312
Iga C et al. Prolonged survival of small intestinal allograft in the rat with cyclosporine A, FK 506, and 15-deoxyspergualin. 1990 Transplant. Proc. pmid:1697118
Marente VC et al. Modigraf administration through jejunostomy in liver transplant recipient: case report. 2013 Transplant. Proc. pmid:24314992
Malireddy SR et al. Altered first-pass effects in a liver transplant recipient explained intraindividual variation in calcineurin inhibitor concentrations: a case report. 2008 Transplant. Proc. pmid:18589198
Weimer R et al. sCD30 and neopterin as risk factors of chronic renal transplant rejection: impact of cyclosporine A, tacrolimus, and mycophenolate mofetil. 2005 Transplant. Proc. pmid:15919463
Cicero A and Lappin JA Pancreas transplantation: experience at University of Texas, Houston. 2010 Jan-Feb Transplant. Proc. pmid:20172339
Escartín A et al. Analysis of pig-MAP after small bowel transplantation in pigs. 1998 Transplant. Proc. pmid:9865377
Malaise J et al. Immunosuppressive drugs after simultaneous pancreas-kidney transplantation. 2005 Jul-Aug Transplant. Proc. pmid:16182827
Zhu Y et al. Prolongation of canine renal allograft survival by combining tacrolimus with antimetabolic agents. 1997 Feb-Mar Transplant. Proc. pmid:9123011
De Paolis P et al. "Immuknow" to measurement of cell-mediated immunity in renal transplant recipients undergoing short-term evaluation. 2011 Transplant. Proc. pmid:21620039
Platz KP et al. Immunosuppressive power and limitations of FK 506 for prevention and treatment of graft-vs-host disease after small bowel transplantation. 1996 Transplant. Proc. pmid:8907933
Zmonarski SC et al. Lowering of Messenger Ribonucleic Acid Toll-Like Receptors 2-4,9 in Peripheral Blood Mononuclear Cells in Kidney Allograft Recipients, Relationships With Immunosuppressive Treatment, and Delayed Graft Function Occurrence. 2016 Transplant. Proc. pmid:27496439
Imanishi M et al. Induction of tolerance by intrathymic injection of donor bone marrow cells in the rat: simultaneous heart and skin allograft model. 1994 Transplant. Proc. pmid:7520615
Lieberman KV et al. FK 506 is a direct glomeruloconstrictor, as determined by electrical resistance pulse sizing (ERPS). 1991 Transplant. Proc. pmid:1721376
Demetris AJ et al. Histopathology of human renal allograft rejection under FK 506: a comparison with cyclosporine. 1991 Transplant. Proc. pmid:1703360
Stratta RJ Optimal immunosuppression in pancreas transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083263
Han DJ et al. A 39-month follow-up study to evaluate the safety and efficacy in kidney transplant recipients treated with modified-release tacrolimus (FK506E)-based immunosuppression regimen. 2012 Transplant. Proc. pmid:22310592
Walgenbach KJ et al. Immunocytes of composite tissue allografts express elevated levels of TGF beta mRNA and protein during chronic rejection. 1997 Feb-Mar Transplant. Proc. pmid:9123418
Chen YB et al. Suitable calcineurin inhibitor concentrations for liver transplant recipients in the Chinese population. 2011 Transplant. Proc. pmid:21693271
Platz KP et al. Incidence and outcome of chronic rejection in CyA- and FK 506-treated patients. 1996 Transplant. Proc. pmid:8962235
Shinozuka H et al. Effect of FK 506 on experimental liver carcinogenesis. 1991 Transplant. Proc. pmid:1721407
Cai X et al. Low-dose of FK 506 and associated blood levels in allotransplantation of rat liver, heart, and skin. 1992 Transplant. Proc. pmid:1379759
Langrehr JM et al. Quadruple versus dual tacrolimus-based induction after liver transplantation: a prospective, randomized trial. 2001 Transplant. Proc. pmid:11377549
Maass E et al. Decrease in serum tacrolimus level and rise in serum creatinine under late addition of cinacalcet in a renal transplant recipient with hyperparathyroidism: a case report. 2007 Transplant. Proc. pmid:18089410
Uber PA et al. Steroid weaning in heart transplantation is associated with decreased B-type natriuretic peptide: surrogate evidence for cardiac adaptation. 2002 Transplant. Proc. pmid:12176598
Vincenti F Tacrolimus (FK 506) in kidney transplantation: five-year survival results of the U.S. multicenter, randomized, comparative trial. 2001 Feb-Mar Transplant. Proc. pmid:11267172
Tahir W et al. Diffuse Alveolar haemorrhage: a fatal complication after alemtuzumab induction therapy in renal transplantation. Transplant. Proc. pmid:25645795
Lagget M et al. Disappearance of diabetes mellitus after conversion from FK 506 to Neoral in two liver transplanted patients. 1998 Transplant. Proc. pmid:9723312
Kovarik JM et al. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. 2006 Transplant. Proc. pmid:17175302
Moura Neto A et al. Clinical Profile of Patients With Diabetes Mellitus and Liver Transplantation: Results After a Multidisciplinary Team Intervention. 2018 Transplant. Proc. pmid:29661438
Ghio L et al. Conversion from tacrolimus to cyclosporine for a non-dose-dependent tacrolimus-induced toxicity, a pediatric kidney transplant recipient case report. 2004 Transplant. Proc. pmid:15251325
Markus BH et al. Daclizumab induction therapy in combination with tacrolimus. 2001 Feb-Mar Transplant. Proc. pmid:11267354
Chamienia A et al. Open prospective study to evaluate cardiovascular risk factors and renal function in 2 dosage regimens of tacrolimus combined with mycophenolate mofetil and steroids in renal transplant patients: 5-year results. 2014 Transplant. Proc. pmid:25380901
González MG et al. Comparison of post-liver transplantation electrocardiographic alterations between cyclosporine- and tacrolimus-treated patients. 1999 Transplant. Proc. pmid:10500652
Abe T et al. Risk factors for development of new-onset diabetes mellitus and progressive impairment of glucose metabolism after living-donor liver transplantation. 2014 Transplant. Proc. pmid:24767367
Starzl TE et al. Notes on FK 506. 1991 Transplant. Proc. pmid:1714647
Badiou S et al. Small dense low-density lipoprotein in renal transplant recipients: a potential target for prevention of cardiovascular complications? 2006 Transplant. Proc. pmid:16980076